跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
SANDOZ SITAGLIPTIN-METFORMIN - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
SANDOZ SITAGLIPTIN-METFORMIN
Authorized
STANDARD
SANDOZ SITAGLIPTIN-METFORMIN
Sandoz Canada, Inc.
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
2731589dc71f5a28
Company
Sandoz Canada, Inc.
Type
Standard
Approval Details
Approval Id
2731589dc71f5a28
Drug Approval Canada Name
SANDOZ SITAGLIPTIN-METFORMIN
Product Name
SANDOZ SITAGLIPTIN-METFORMIN
Status
Marketed
Status Date
2023-01-05
Original Market Date
2023-01-05
Din
02503964
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Prescription
Ahfs
68:20.05
Atc Original
A10BD07 METFORMIN AND SITAGLIPTIN
Atc Name
a 10 bd 07
Aig Number
0252656002
Company Name
Sandoz Canada, Inc.
Company Address
4600 Rue Armand-Frappier, Saint-Hubert, Quebec, Canada, J3Z 1G5
Company Detail Path
/organization/sandoz-canada-inc
Company Information
Pharmaceutical Company Name
Sandoz Canada, Inc.
Country Name
Canada
Website
http://www.sandoz.ca
Active Ingredients
METFORMIN HYDROCHLORIDE
850 MG
SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE)
50 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
2731589dc71f5a28
Type
Standard
Back to Health Canada Approvals